AbbVie Inc.?began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries. The new company, ?which is?focused on developing leading-edge therapies and innovations, was founded on?January 1, 2013 following the?separation from Abbott Laboratories.

Among the products in development is?ABT-414, an investigational anti-EGFR (epidermal growth factor receptor) monoclonal antibody drug conjugate or ADC being evaluated for the treatment of patients with various cancer and tumor types. As an ADC, ABT-414 is designed to be stable in the bloodstream and only release the potent cytotoxic agent once inside targeted cancer cells, thereby reducing the toxic side effects of traditional chemotherapy while enhancing anti-tumor activity. Being developed by AbbVie researchers, ABT-414 is currently being investigated in Phase I/II for the treatment of glioblastoma multiforme, the most common and most aggressive malignant primary brain tumor. ABT-414 is also in clinical trials for the treatment of patients with squamous cell tumors.

1 N. Waukegan Rd.
North Chicago, IL, 60064


Advertisement #5